Immunology

Biomedical/pharma, Immunology, Oncology

Founded as a spin-off from the French Blood Bank, PDC*line Pharma is focused on developing immunotherapeutic vaccines. These vaccines contain their proprietary and unique plasmacytoid dendritic cell (PDC) line, whose remarkable characteristics make it excellently suited for immunotherapy. By boosting the immune system with their vaccine in combination with checkpoint inhibitors, PDC*line Pharma aims to help the currently large group of non-responders to immunotherapy.
Although immunotherapy in cancer is booming, it isn’t by any measure an easy field to navigate. Many oncology ventures willing to explore this new terrain [...]

An excerpt from the BioVox White paper on Cancer Immunotherapy.

Over the years, the perception of inflammatory diseases has changed drastically. The advent of cytokine inhibitors meant great improvement to many patients, especially those suffering from rheumatoid arthritis. However, these treatments remain symptomatic. Together with Janssen Pharmaceutica, world-renowned rheumatologist Lars Klareskog is ready to take the research and treatment of inflammatory joint disease to the next level.

It has long been known that exposure to microbes can play a protective role against the subsequent development of asthma. Researchers from GIGA of the University of Liège provide an explanation and propose to use this discovery to set up a strategy of cell therapy to treat asthma in humans. Their discovery is published in Immunity.

We write about change — about impact and consequences, about discoveries and the people behind them. This time, we introduce you to Roosmarijn Vandenbroucke, a discovery scientist at IRC-VIB and a professor at Ghent University. She gives us an eagle’s-eye view of her group’s latest research, which has the potential to impact the management of patients with neurodegenerative and neuroinflammatory diseases.
Houston (Texas, USA) has been home to Jeroen Pollet since August 2011. He arrived as a Fulbright scholar; now he is an assistant professor at Baylor College of Medicine (BCM), and also the director of the Formulation Development Unit at the Sabin Vaccine Institute & Texas Children`s Hospital Center for Vaccine Development.   In these roles, he develops new vaccines against neglected tropical diseases and studies the interactions of vaccine antigens  with immunostimulatory agents in relation to immune responses and vaccine efficacy.